These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12495173)

  • 61. Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone.
    Atar S; Freedberg NA; Antonelli D; Rosenfeld T
    Pacing Clin Electrophysiol; 2003 Mar; 26(3):785-6. PubMed ID: 12698686
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation.
    Goto M; Sato M; Kitazawa H; Takahashi M; Fuse K; Saito A; Okabe M; Aizawa Y
    Intern Med; 2014; 53(15):1629-31. PubMed ID: 25088875
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Management of prolonged QT interval and torsades de pointes in the intoxicated patient.
    Kan AA; de Lange DW; Donker DW; Meulenbelt J
    Neth J Med; 2014 Apr; 72(3):119-26. PubMed ID: 24846924
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
    Gury C; Canceil O; Iaria P
    Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Torsade de pointes during anti-arrhythmia treatment with amiodarone].
    Schlienger RG; Haefeli WE; Lüscher TF
    Schweiz Rundsch Med Prax; 1993 Feb; 82(6):173-5. PubMed ID: 7679520
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review.
    Hunt N; Stern TA
    Psychosomatics; 1995; 36(6):541-9. PubMed ID: 7501784
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report.
    Katapadi K; Kostandy G; Katapadi M; Hussain KM; Schifter D
    Angiology; 1997 Sep; 48(9):821-6. PubMed ID: 9313632
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
    Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
    Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ciprofloxacin-induced torsade de pointes.
    Flanagan MC; Mitchell ES; Haigney MC
    Int J Cardiol; 2006 Nov; 113(2):239-41. PubMed ID: 16386810
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [A case of torsades de pointes probably caused by trimetaphan intoxication].
    Hirata K; Kyushima M; Kawamitsu K; Asato H; Sunagawa H; Uehara H
    J Cardiol; 1994; 24(3):243-7. PubMed ID: 8207640
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Congenital long QT syndrome: severe torsades de pointes provoked by epinephrine in a digenic mutation carrier.
    Tan VH; Duff H; Kuriachan V; Gerull B
    Heart Lung; 2014; 43(6):541-5. PubMed ID: 25236808
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Amiodarone-induced torsade de pointes in a patient with wolff-Parkinson-White syndrome.
    Badshah A; Mirza B; Janjua M; Nair R; Steinman RT; Cotant JF
    Hellenic J Cardiol; 2009; 50(3):224-6. PubMed ID: 19465366
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The possible role of propofol in drug-induced torsades de pointes: A real-world single-center analysis.
    Abrich VA; Ramakrishna H; Mehta A; Mookadam F; Srivathsan K
    Int J Cardiol; 2017 Apr; 232():243-246. PubMed ID: 28100427
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
    Drici MD; Clément N
    Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Loperamide Induced Recurrent Torsades de Pointes: A Case Report.
    Jackson GG; Lopez CR; Bermudez ES; Hill NE; Roden DM; Ely EW; Stollings JL
    J Pharm Pract; 2022 Oct; 35(5):791-795. PubMed ID: 33779357
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predictive factors of ventricular fibrillation triggered by pause-dependent torsades de pointes associated with acquired long QT interval: role of QT dispersion and left ventricular function.
    Da Costa A; Chalvidan T; Belounas A; Messier M; Viallet M; Mansour H; Lamaison D; Djiane P; Isaaz K
    J Cardiovasc Electrophysiol; 2000 Sep; 11(9):990-7. PubMed ID: 11021469
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Torsade de pointes tachycardia in a patient on dronedarone therapy.
    Huemer M; Sarganas G; Bronder E; Klimpel A; Garbe E; Haverkamp W
    Pharmacotherapy; 2015 May; 35(5):e61-5. PubMed ID: 25823967
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study.
    Houltz B; Darpö B; Edvardsson N; Blomström P; Brachmann J; Crijns HJ; Jensen SM; Svernhage E; Vallin H; Swedberg K
    Pacing Clin Electrophysiol; 1998 May; 21(5):1044-57. PubMed ID: 9604236
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Methadone-induced torsades de pointes: a twist of fate.
    Thanavaro KL; Thanavaro JL
    Heart Lung; 2011; 40(5):448-53. PubMed ID: 21411146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.